Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brightline-4
2023-504522-19-00Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 3, open-label trial of brigimadlin in dedifferentiated liposarcoma (DDL) (2 cohorts), sponsored by Boehringer Ingelheim. Primary endpoints: Treatment-emergent adverse events (TEAEs) and Grade ≥3 TEAEs. Started May 2024; status: completed.
02
Drugs
brigimadlin
03
Conditions
dedifferentiated liposarcoma (DDL)
Beyond the preview
Go deeper on 2023-504522-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504522-19-00.